The nation of Zimbabwe has declined a major US healthcare agreement worth $367m (272 million pounds) over five years over the United States' demand for sensitive biological samples.
This rejection was revealed following a internal memorandum from December was leaked, which showed President Emmerson Mnangagwa believed the deal was "lopsided".
An official spokesperson has since stated that the US was requesting genetic material for scientific study and profit while was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged more talks to secure a deal suitable to all parties so the nation's critical HIV programme can be sustained.
Broader Background
This rejection follows a similar case in Kenya, where a court halted a similar deal with the US following legal challenges were filed about the safety of citizens' health data.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to boost openness and accountability.
As per reports, 16 African countries have to date agreed to similar agreements, representing over $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any equivalent promise of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"In essence, our nation would provide the raw materials for medical research with no assurance that the resulting innovations would be accessible to our citizens should a future health crisis arise."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of bilateral deals were undermining structures already set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is intended to guarantee that when a nation contributes its information, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We encourage further discussions with our American counterparts on how subsequent co-operation could be arranged in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body expressed it understood the government's concerns, but urged that negotiations need to persist given that a large portion of the nation's Aids initiatives depended on international support.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," it added.
The situation highlights the ongoing debate between receiving crucial international aid and protecting national sovereignty in an ever more data-driven world.